Physician profile
James Daniel Dewar
NPI 1013128222
$1,334.06
in general payments reported to CMS, 2019-2025
11 companies · $531 in 2025
The $531 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2021: $16.67 · 2022: $143 · 2023: $170 · 2024: $371 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,071.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $322.26 | 2025 | |
| Biotronik INC. | $232.03 | 2019-2024 | Acticor 7 Vr-T Dx, Amvia Edge |
| Bard Peripheral Vascular, INC. | $230.96 | 2024-2025 | Rotarexs 6 F X 135 Cm, Lifestream, Lutonix Drug Coated Balloon |
| Abbott Laboratories | $163.94 | 2019-2025 | Diamondback Coronary, Emboshield Nav6, Esprit |
| Impulse Dynamics (USA) INC. | $100.21 | 2023 | Optimizer |
| Medtronic, INC. | $94.05 | 2022-2024 | In.Pact Av, Hawkone, In.Pact Admiral |
| Recor Medical INC | $89.20 | 2025 | Paradise Ultrasound Renal Denervation System |
| Siemens Medical Solutions USA, INC. | $29.47 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $28.00 | 2019 | |
| Becton, Dickinson and Company | $24.85 | 2025 | Rotarexs 6 F X 135 Cm |
| Boston Scientific Corporation | $19.09 | 2024 | S-Icd System Magnet |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Dewar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.